missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SLAMF9 Polyclonal Antibody
Description
Recommended positive controls: Jurkat, Raji. Predicted reactivity: Human (99%), Rhesus Monkey (92%), Chimpanzee (97%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
The SLAM (signalling lymphocyte activation molecule) family is a novel group of receptors on T cells in modulating the immune response. SLAMF9, also known as CD2F-10 or CD84 homolog, is a 289 amino acid type I transmembrane protein that shares 58% identity with the mouse protein. The SLAMF9 protein is predominantly expressed in hematopoietic tissues and contains an extracellular region with only two N-linked glycosylation sites, a 20-residue transmembrane region and a highly positively charged 30-residue cytoplasmic tail, suggesting a role for SLAMF9 as an adhesion molecule. SLAMF9 is thought to function in the immune response as a coreceptor for lymphocyte activation.
Specifications
Specifications
| Antigen | SLAMF9 |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 0.85 mg/mL |
| Conjugate | Unconjugated |
| Formulation | 0.1M tris glycine with 20% glycerol and 0.01% thimerosal; pH 7 |
| Gene | SLAMF9 |
| Gene Accession No. | Q96A28 |
| Gene Alias | 2310026I04Rik; AI462096; CD2 antigen family, member 10; CD2 family member 10; CD2F10; CD2F-10; CD84 homolog 1; CD84H1; CD84-H1; cluster of differentiation 2 antigen family member 10; cluster of differentiation 84 homolog 1; RP11-48O20.3; SF2001; signaling lymphocytic activation molecule family member 2001; signaling lymphocytic activation molecule family member 9; SLAM family member 9; SLAMF9; UNQ1938/PRO4421 |
| Gene Symbols | SLAMF9 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?